Alto Neuroscienc Stock Price, News & Analysis

Alto Neuroscience (NYSE:ANRO) has announced positive pharmacodynamic results from its exploratory Phase 2 proof-of-concept trial of ALTO-203, a novel oral histamine H3 inverse agonist for major depressive disorder (MDD) patients. The trial successfully identified a biomarker (EEG theta/beta ratio) for patient selection and demonstrated the drug's pro-cognitive and wake-promoting effects.

Key findings include significant improvements in sustained attention (p<0.05 at 25µg dose), increased wakefulness confirmed by wearable devices (p<0.05 at 25µg; p<0.001 at 75µg), and improvements in the MADRS score (2 points at week 3 for 25µg dose). The study enrolled 69 patients and showed ALTO-203 was well-tolerated, with insomnia being the most common side effect.

Alto Neuroscience (NYSE: ANRO) has acquired a novel dopamine agonist portfolio from Chase Therapeutics Corporation, including ALTO-207 (formerly CTC-501) for treatment resistant depression (TRD). ALTO-207 is a fixed-dose combination of pramipexole and ondansetron, designed to provide rapid antidepressant effects while reducing adverse events. The drug showed significant positive results in a Phase 2a study, demonstrating greater improvements on MADRS compared to placebo (Week 8 Cohen's d = 1.1, p<0.05). Alto plans to initiate a potentially pivotal Phase 2b trial by mid-2026, with topline data expected in 2027. The acquisition adds a major late-stage clinical readout without affecting Alto's current cash runway, which extends into 2028. The company's strategic focus on dopamine biomarkers in depression positions them to advance this therapeutic approach for TRD patients.

Alto Neuroscience (NYSE: ANRO) presented data at the 2025 ASCP Annual Meeting regarding ALTO-300 (agomelatine) for Major Depressive Disorder (MDD). The presentation highlighted the drug's safety profile and biomarker validation. ALTO-300 is being developed as a 25mg adjunctive treatment for MDD patients with a specific EEG biomarker. The drug acts as a melatonin agonist and 5-HT2C antagonist. Key findings include: - The 25mg dose shows similar antidepressant efficacy to 50mg while avoiding liver enzyme elevation concerns - Phase 2a trial (239 patients) reported no significant liver function test elevations - Most common side effect was headache - Ongoing Phase 2b trial shows favorable safety profile - Preclinical and clinical evidence supports the mechanistic link between ALTO-300 and its EEG biomarker for patient selection While agomelatine is approved in Europe and Australia at both 25mg and 50mg doses, it remains unapproved in the United States.

Alto Neuroscience (NYSE: ANRO), a clinical-stage biopharmaceutical company developing precision medicines for neuropsychiatric disorders, has announced its participation in two major investor conferences in June 2025. The company will present at the Jefferies Global Healthcare Conference (June 3-5) in New York, featuring a fireside chat on June 5 at 2:00 pm ET. Additionally, Alto will participate in the H.C. Wainwright 6th Annual Neuro Perspectives Conference (June 16-17) with an on-demand presentation available from June 17 at 7:00 am ET. Both events will include one-on-one investor meetings, and presentations will be accessible via webcast on Alto's website.

Alto Neuroscience (NYSE: ANRO) reported Q1 2025 financial results and pipeline updates. The company maintains a strong cash position of $161.3 million, expected to fund operations into 2028. Key clinical trials progress includes: ALTO-203 for major depressive disorder (MDD) with topline data expected in Q2 2025, ALTO-101 for schizophrenia in H2 2025, ALTO-300 Phase 2b trial in MDD with data expected mid-2026, and ALTO-100 for bipolar depression with results in H2 2026. Q1 2025 financial results showed R&D expenses of $10.0 million, G&A expenses of $5.7 million, and a net loss of $15.2 million. The company's biomarker-driven approach in neuropsychiatric drug development continues to advance with new data presentations supporting their precision medicine strategy.

Alto Neuroscience (NYSE: ANRO) presented significant findings at the Society of Biological Psychiatry Annual Meeting 2025, highlighting advancements in their precision psychiatry pipeline. The company successfully identified and validated an EEG-based biomarker for predicting placebo response in major depressive disorder (MDD) patients, potentially improving clinical trial efficiency.

Key developments include:

• Validation of EEG biomarker's ability to predict placebo response in MDD trials, with significant correlations in ALTO-100 Phase 2b and EMBARC sertraline trials
• New mechanistic insights linking ALTO-300's action to EEG biomarker patterns through 5-HT2C antagonism and dopamine regulation
• Positive results from ALTO-101's preclinical rescue study, demonstrating its potential for treating cognitive impairment in schizophrenia
• ALTO-203 showed promise in reversing anhedonia-like behavior in preclinical studies

Alto Neuroscience (NYSE: ANRO), a clinical-stage biopharmaceutical company developing precision medicines for neuropsychiatric disorders, has announced its participation in the upcoming JonesResearch Virtual CNS Day.

The company's management team will deliver a presentation on Tuesday, April 29, 2025, at 12:30 pm ET and engage in one-on-one investor meetings. Interested parties can access the presentation through a live webcast available on the Events and Presentations page in the Investors section of Alto's website, with a replay option available after the event.

Alto Neuroscience (NYSE: ANRO) reported its full-year 2024 financial results and pipeline updates. The company ended 2024 with a strong cash position of $169 million, expected to fund operations into 2028. Key financial metrics include R&D expenses of $47.0 million, G&A expenses of $21.6 million, and a net loss of $61.4 million.

Pipeline highlights include:

• ALTO-300: Favorable interim analysis in Phase 2b MDD trial with topline results expected mid-2026
• ALTO-203: Completed enrollment in Phase 2 MDD trial with data expected Q2 2025
• ALTO-101: New transdermal formulation showing improved drug exposure; Phase 2 schizophrenia trial data expected H2 2025
• ALTO-100: Ongoing Phase 2b trial in bipolar depression with data expected H2 2026

The company strengthened its patent portfolio with new grants covering ALTO-300 and ALTO-100 in biomarker-defined populations, extending protection until 2044 and 2043 respectively.

High-Trend International Group (NASDAQ: HTCO) has announced significant leadership changes, appointing Christopher Nixon Cox as Chairman and Bo Cui as Chief Legal Officer. Cox, who replaces Jinyu Chang (who remains a director), brings extensive experience in global markets and sustainability. He currently serves as CEO of Lightswitch Capital, Argali Carbon , and BioSource Feed , with previous roles including Vice Chairman of Brightsphere, Inc.

Cox's appointment aims to drive HTCO's strategic growth in innovation-driven sectors, particularly focusing on maritime low-carbon initiatives and ocean-based decarbonization. Bo Cui joins with over 20 years of experience in cross-border finance and M&A, having previously led $10 billion in strategic deals at HNA Group.

CEO Shixuan He emphasized that Cox's expertise in capital markets and green technologies aligns with the company's vision, while Cui's background in law and emerging technologies will strengthen their legal strategy and risk management during global expansion.